FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
New subcutaneous treatment shows 42% response rate for recurrent head and neck carcinoma patients.
1Accelerated FDA Approval Granted
The FDA has granted accelerated approval to subcutaneous amivantamab and hyaluronidase, marketed as Rybrevant Faspro, for treating adults with recurrent or metastatic head and neck squamous cell carcinoma. This regulatory decision specifically targets patients whose disease progressed following platinum-based chemotherapy and immunotherapy, providing a new therapeutic pathway for a challenging condition.
2Clinical Trial Efficacy Results
Approval was based on the phase Ib/II OrigAMI-4 trial, which included 102 participants. The study demonstrated an overall response rate of 42%, with 15% of patients achieving a complete response. Furthermore, 56% of those who responded to the therapy maintained their clinical improvement for a duration of six months or longer.
3Addressing Unmet Clinical Needs
Historically, patients with this specific form of cancer have faced limited treatment options and poor clinical outcomes, with existing therapies often yielding response rates of only 20%. By providing a new option that targets tumor progression, this therapy aims to improve the quality of life for patients with advanced disease stages.
4Dual Targeting Mechanism Explained
Amivantamab functions by simultaneously targeting EGFR and MET, which are two critical drivers of tumor progression in head and neck cancers. This dual-targeting approach distinguishes the drug from traditional treatments, potentially offering a more effective way to inhibit cancer cell growth in patients who have exhausted standard chemotherapy and immunotherapy options.
5Exclusions and Patient Criteria
The FDA noted that this specific approval does not extend to patients diagnosed with human papillomavirus-associated oropharyngeal squamous cell carcinoma. Clinicians must carefully screen patients to ensure they meet the criteria of having recurrent or metastatic disease that has failed to respond to prior platinum-based chemotherapy and standard immunotherapy regimens.
6Safety Warnings and Precautions
The prescribing information for the new therapy includes significant warnings regarding potential adverse reactions. These include risks of hypersensitivity and administration-related reactions, interstitial lung disease, pneumonitis, and dermatologic issues. Additionally, the drug carries warnings for ocular toxicity and embryo-fetal toxicity, requiring careful monitoring by healthcare providers throughout the entire treatment course.
7Ongoing Confirmatory Research Studies
While the current approval is accelerated, full regulatory authorization may depend on results from the ongoing phase III OrigAMI-5 study. This confirmatory trial is currently evaluating the efficacy of subcutaneous amivantamab when combined with carboplatin and pembrolizumab as a potential first-line treatment for patients suffering from recurrent or metastatic head and neck cancer.
8Broader Therapeutic Context
This approval follows previous FDA actions regarding amivantamab, including its 2024 authorization for non-small cell lung cancer patients with EGFR exon 20 insertion mutations. By expanding the use of this subcutaneous formulation, the agency continues to build on the drug's established profile, providing oncologists with versatile tools to manage complex, treatment-resistant malignancies.
Original article: MedPage Today — FDA Approves Dual-Targeted Therapy for Head and Neck Cancer